Cipla Limited is an Indian multinational pharmaceutical and biotechnology company. Founded in 1935, Cipla is headquartered in Mumbai, Maharashtra, India. It is one of the largest pharmaceutical companies in India and has a global presence with operations in over 80 countries.
Cipla is known for its focus on providing affordable and accessible medicines to people worldwide. The company develops and manufactures a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, and active pharmaceutical ingredients (APIs).
In addition to its pharmaceutical business, Cipla is involved in the development and production of biosimilars, which are biological products that are highly similar to and have comparable efficacy and safety profiles as approved reference biologics. In this Article we will discuss about Cipla Share Price Target 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030.
Table of Contents
Business Model of Cipla Limited
Cipla Limited follows a business model that revolves around providing affordable and accessible healthcare solutions. The key elements of Cipla’s business model include:
1. Affordable Medicines: Cipla is committed to producing high-quality medicines at affordable prices. The company aims to make essential drugs and therapies accessible to a wide range of patients, particularly in developing countries. This approach has helped Cipla establish a strong presence in the global pharmaceutical market.
2. Research and Development (R&D): Cipla places significant emphasis on research and development activities. The company invests in cutting-edge technologies and innovative drug formulations to develop new and improved treatments. By focusing on R&D, Cipla aims to address unmet medical needs and introduce cost-effective solutions in various therapeutic areas.
3. Global Reach: Cipla has a strong global presence, with operations in more than 80 countries. The company actively participates in partnerships, collaborations, and licensing agreements to expand its reach and make its products available in different markets. Cipla’s international presence enables it to cater to diverse patient populations and contribute to healthcare access on a global scale.
4. Diversified Product Portfolio: Cipla has a diverse range of products, including prescription drugs, over-the-counter medications, and APIs. The company covers multiple therapeutic areas, such as respiratory, cardiovascular, anti-infectives, central nervous system, dermatology, and oncology. This diversified portfolio allows Cipla to address a wide spectrum of healthcare needs and serve different patient populations.
5. Focus on Biosimilars: Cipla has ventured into the development and production of biosimilars, which are highly similar versions of approved reference biologics. By manufacturing biosimilars, Cipla aims to provide more affordable alternatives to expensive biologic therapies, thereby improving access to advanced treatments for conditions such as cancer, autoimmune diseases, and other chronic disorders.
6. Commitment to Sustainability: Cipla is committed to sustainable practices in its operations. The company focuses on reducing its environmental impact, promoting employee well-being, and contributing to the communities in which it operates. Cipla’s sustainability efforts align with its mission to provide affordable healthcare solutions while minimizing its ecological footprint.
Shareholding of Cipla Limited
As of March 31, 2023, the shareholding pattern of Cipla Limited was as follows:
· Promoter and Promoter Group: 33.41%.
· Foreign Institutional Investors (FIIs): 27.29%.
· Indian Institutional Investors (IIs): 19.76%.
· GDR: 0.42%.
· Others: 19.12%.
The top five shareholders of Cipla Limited were:
· Otsuka Holdings Co., Ltd.: 25.44%.
· Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: 15.01%.
· Cipla Limited: 9.92%.
· Ono Pharmaceutical Co., Ltd.: 13.40%.
· Zydus Lifesciences Limited: 20.91%
Cipla limited Share
Cipla Limited Share listed on the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE).
As of June 14, 2023, Cipla’s share price on the NSE was INR 976.90/- Cipla Share 52 week high at Rs. 1185.25/- & 52 week low Rs.852/-. The P/E Ratio of Cipla Share is 28.15 & Dividend Yield is 0.87%.
| Company Name | Cipla Limited |
| Share Name | CIPLA |
| Sector | Pharmaceutical and Biotechnology |
| Headquater | Mumbai |
| Foundation | 1935 |
| Key Person | Umang Vohra (CEO) |
| Market Cap | 78,825.47 Crores Rs. |
| Revenue | 16,247.39 Crore Rs |
| Official Website | Click Here |
Cipla Share Price Target 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2040, 2050
| Year | First Target | Second Target |
| 2023 | 1020 | 1050 |
| 2024 | 1075 | 1140 |
| 2025 | 1160 | 1210 |
| 2026 | 1240 | 1320 |
| 2027 | 1345 | 1420 |
| 2028 | 1445 | 1525 |
| 2029 | 1570 | 1660 |
| 2030 | 1690 | 1780 |
| 2040 | 4250 | 5290 |
| 2050 | 8340 | 9400 |
Note:- “That these share price targets for “Cipla Share” are only provided for the purpose of reference and that this prediction will only hold true in the event that there is optimism in the market. Any uncertainties regarding the company or the current state of the global market will not be addressed in this analysis.”
Buy Cipla Share in India’s Best Trading Platform @ 0 Rs. Brokerage
Annual Result Summary of Cipla Limited
Here is a summary of Cipla’s annual results for the financial year 2022-2023:
- Revenue: Cipla’s revenue for the year ended March 31, 2023, was INR 2,20,851 crore, which represents increase of 13.7% compared to the previous year.
- Net profit: The company’s net profit for the year was INR 25,595 crore, an decrease of 6.6% compared to the previous year.
- Earnings per share (EPS): The earnings per share for the year was INR 30.61, which represents a decrease of 8.18% compared to the previous year.
- EBITDA: The company’s EBITDA for the year was INR 11.74 Billion.
Cipla Share Price Target 2023
The company’s performance was driven by strong growth in its domestic and international businesses. Domestic sales grew by 17.1% to Rs. 100,759 crore, while international sales grew by 10.6% to Rs. 120,092 crore.
Cipla share price target 2023 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2023 | ₹1020 | ₹1050 |
Cipla Share Price Target 2024
Cipla’s growth was also supported by its focus on innovation. The company launched 10 new products during the year, including a generic version of the cancer drug Revlimid. Cipla is also investing in research and development, with a focus on developing new treatments for diseases such as cancer, HIV/AIDS, and tuberculosis.
Cipla share price target 2024 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2024 | ₹1075 | ₹1140 |
Cipla Share Price Target 2025
Cipla’s strong performance has been recognized by investors. The company’s stock price has increased by over 20% in the past year. Cipla is well-positioned for continued growth in the future, as it continues to focus on innovation and expanding its reach into new markets.
Cipla share price target 2025 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2025 | ₹1160 | ₹1210 |
Cipla Share Price Target 2026
Cipla’s product portfolio covers various therapeutic areas, including respiratory, cardiovascular, anti-infectives, central nervous system, dermatology, and oncology, among others. The company has made significant contributions in the fight against HIV/AIDS by manufacturing and supplying low-cost antiretroviral drugs, helping to improve access to treatment in developing countries.
Cipla share price target 2026 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2026 | ₹1240 | ₹1320 |
Cipla Share Price Target 2027
Cipla has a diverse range of products that cover multiple therapeutic areas, including respiratory, cardiovascular, anti-infectives, central nervous system, dermatology, and oncology. Its portfolio includes both generic and branded medications.
Cipla share price target 2027 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2027 | ₹1345 | ₹1420 |
Cipla Share Price Target 2028
Cipla has a significant global presence and operates in more than 80 countries around the world. The company exports its products to various markets, including the United States, Europe, Africa, Asia, and Latin America.
Cipla share price target 2028 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2028 | ₹1445 | ₹1525 |
Cipla Share Price Target 2029
Cipla Limited’s business model combines a commitment to affordability, global reach, research and development, diversified product offerings, and sustainability. By adhering to these principles, Cipla strives to make a positive impact on healthcare access and improve patient outcomes worldwide.
Cipla share price target 2029 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2029 | ₹1570 | ₹1660 |
Cipla Share Price Target 2030
Cipla places a strong emphasis on research and development (R&D). The company has a dedicated R&D center in Mumbai and collaborates with leading academic institutions and research organizations to drive innovation and develop new drugs and formulations.
Cipla share price target 2030 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2030 | ₹1690 | ₹1780 |
Dividend History of Cipla Share
Here is a brief overview of CIPLA’s dividend history over the past few years:
- In 2023, Company declared a final dividend of Rs. 8.5 per share.
- In 2022, Company declared a final dividend of Rs.5 per share.
- In 2021, Company declared a final dividend of Rs. 5 per share.
- In 2020, Company declared a final dividend of Rs. 3 per share.
Joint venture & Subsidiaries of Cipla Limited
Here are some notable joint ventures and subsidiaries of Cipla:
Joint Ventures:
1. Cipla Medpro South Africa Limited: Cipla acquired a majority stake in Medpro, a leading pharmaceutical company in South Africa, and formed a joint venture called Cipla Medpro. This joint venture enables Cipla to expand its presence in the African market and enhance access to affordable medicines in the region.
2. Cipla BioTec: Cipla formed a joint venture with BioMab, a Hong Kong-based biotechnology company, to establish Cipla BioTec. This joint venture focuses on the development and commercialization of biosimilars for global markets.
3. Cipla USA: Cipla has a joint venture with a group of investors to operate in the United States under the name Cipla USA. This joint venture allows Cipla to strengthen its presence in the U.S. market and enhance its offerings to American patients.
Subsidiaries:
1. Cipla Health Limited: Cipla Health is a subsidiary of Cipla Limited that focuses on the consumer healthcare segment. It offers a range of over-the-counter (OTC) products and wellness solutions.
2. Cipla New Ventures: Cipla New Ventures is a subsidiary of Cipla that focuses on nurturing innovation and exploring new business opportunities in healthcare. It actively engages in strategic investments, collaborations, and partnerships to drive growth and diversification.
3. Cipla BioTec Pvt. Ltd.: In addition to the joint venture mentioned earlier, Cipla also has a subsidiary called Cipla BioTec Pvt. Ltd. This subsidiary focuses on the research, development, and manufacturing of biosimilars.
Future Plan of Cipla Limited
Cipla Limited has a number of future plans, including:
· Expanding its global reach: Cipla plans to expand its global reach by increasing its presence in emerging markets, such as Africa and Latin America. The company also plans to strengthen its presence in developed markets, such as the United States and Europe.
· Investing in research and development: Cipla plans to invest heavily in research and development (R&D) in order to develop new drugs and therapies. The company also plans to invest in R&D for new manufacturing processes and technologies.
· Focusing on specialty products: Cipla plans to focus on specialty products, such as oncology and respiratory products. The company also plans to focus on products that address unmet medical needs.
· Strengthening its digital capabilities: Cipla plans to strengthen its digital capabilities in order to improve its customer service, marketing, and sales. The company also plans to use digital technologies to improve its manufacturing processes and supply chain management.
Cipla is a well-established pharmaceutical company with a strong track record of innovation and growth. The company is well-positioned to achieve its future plans and continue to be a leader in the pharmaceutical industry.
FAQs –
There are a few reasons why you might want to consider investing in Cipla shares.
· Strong financial performance: Cipla is a financially strong company with a long history of profitability. In the past three years, the company has generated a compound annual growth rate (CAGR) of 17.26% in its net profit.
· Consolidated market share: Cipla is one of the leading pharmaceutical companies in India, with a consolidated market share of 10.5% in the domestic market and 4.5% in the global market. The company has a strong presence in both developed and emerging markets.
· Focus on innovation: Cipla is a research-driven company that is constantly innovating new products and therapies. In the past three years, the company has launched over 100 new products.
· Strong management team: Cipla is managed by a strong and experienced team of executives. The company’s chairman and managing director, Umang Vohra, is a highly respected figure in the pharmaceutical industry.
There are a few reasons why you might not want to invest in Cipla shares.
· The company has been facing regulatory challenges. In November 2022, the US Food and Drug Administration (USFDA) placed Cipla’s Goa manufacturing facility under an “official action indicated” (OAI) status. This means that the FDA has found objectionable conditions at the facility and that regulatory action is being considered. The OAI status has led to delays in the launch of new products and has also raised concerns about the company’s compliance with regulatory standards.
· The company’s growth has slowed. Cipla’s revenue growth has slowed in recent years. In the fiscal year 2023, the company’s revenue grew by just 5%. This slowdown is due to a number of factors, including increased competition from generic drugmakers, pricing pressure from payers, and the ongoing regulatory challenges.
· The company’s valuation is high. Cipla’s shares are trading at a premium valuation. The company’s price-to-earnings ratio (P/E) is currently at 25 times, which is higher than the average P/E ratio for the Indian pharmaceutical industry. This high valuation makes Cipla shares a less attractive investment.
Cipla is a strong company with a good track record of profitability. future price of cipla share in 2023 is Rs.1020 to Rs.1050.
Target price of cipla in 2025 will be Rs.1150.
